News
IRWD
4.175
+3.09%
0.125
Weekly Report: what happened at IRWD last week (0803-0807)?
Weekly Report · 1d ago
Ironwood Pharmaceuticals (IRWD) Stock Faces A Sentiment Check After Raised Guidance
Simply Wall St · 4d ago
Ironwood Pharmaceuticals’ Earnings Call Highlights LINZESS Surge
TipRanks · 5d ago
Ironwood Pharmaceuticals Q2 Earnings Call Highlights
NASDAQ · 5d ago
*Ironwood Pharmaceuticals Raises FY26 View To Rev $460M-$485M >IRWD
Dow Jones · 5d ago
Ironwood Pharmaceuticals reports mixed Q2 results; raises FY26 outlook
Seeking Alpha · 5d ago
*Ironwood Pharmaceuticals Raises 2026 Full-Yr Fincl Guidance
Dow Jones · 5d ago
*Ironwood Pharmaceuticals 2Q Adj EPS 31c >IRWD
Dow Jones · 5d ago
*Ironwood Pharmaceuticals 2Q Net $51.3M >IRWD
Dow Jones · 5d ago
*Ironwood Pharmaceuticals 2Q EPS 31c >IRWD
Dow Jones · 5d ago
*Ironwood Pharmaceuticals 2Q Rev $113M >IRWD
Dow Jones · 5d ago
Press Release: Ironwood Pharmaceuticals Raises -3-
Dow Jones · 5d ago
Rare Stock Picks In July 2026 - From 22 Discerning Analysts
Seeking Alpha · 6d ago
Weekly Report: what happened at IRWD last week (0727-0731)?
Weekly Report · 08/03 09:53
Buy The Dip: 2 Top Undervalued Stocks Averaging 394% Forward EPS Growth
Seeking Alpha · 07/31 13:00
Press Release: Ironwood Pharmaceuticals to Host Second Quarter 2026 Investor Update Call
Dow Jones · 07/30 20:50
Ironwood Pharmaceuticals to Host Second Quarter 2026 Investor Update Call
Barchart · 07/30 15:05
Ironwood Pharmaceuticals: One Trial Stands Between Bargain And Bust
Seeking Alpha · 07/30 13:43
Top profitable small caps trading at bargain P/E multiples during Q2 earnings
Seeking Alpha · 07/27 13:09
Weekly Report: what happened at IRWD last week (0720-0724)?
Weekly Report · 07/27 09:56
More
Webull provides a variety of real-time IRWD stock news. You can receive the latest news about Ironwood through multiple platforms. This information may help you make smarter investment decisions.
About IRWD
Ironwood Pharmaceuticals, Inc. is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI), and rare diseases. It is focused on the development and commercialization of GI product opportunities in areas of significant unmet need. LINZESS (linaclotide), its commercial product, is indicated for adult men and women suffering from irritable bowel syndrome with constipation (IBS-C), or chronic idiopathic constipation (CIC), and for pediatric patients ages 6-17 years-old suffering from functional constipation (FC). Linaclotide is available under the trademarked name CONSTELLA to adult men and women suffering from IBS-C or CIC and pediatric patients. The Company is also engaged in advancing apraglutide, a synthetic long-acting peptide analog of glucagon-like peptide-2 (GLP-2), for short bowel syndrome (SBS), patients who are dependent on parenteral support.